Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251511 | 0.80 | MPO (0.42) | MPOCACNA1HPSMB8PSMB9PSMB5 | |
| SCHEMBL22353868 | 0.79 | MPO (0.37) | MPOCACNA1HPSMB8PSMB9PSMB5 | |
| SCHEMBL3433903 | 0.75 | MPO (0.43) | MPOCACNA1HPSMB8PSMB9PSMB5 | |
| SCHEMBL16666980 | 0.74 | MPO (0.42) | MPOCACNA1HPSMB8PSMB9PSMB5 | |
| Hydrochloric Acid SCHEMBL22031938 | 0.74 | MPO (0.45) | MPOCACNA1HPSMB8PSMB9PSMB5 | |
| SCHEMBL22084225 | 0.74 | MPO (0.45) | MPOCACNA1HPSMB8PSMB9PSMB5 | |
| SCHEMBL24258778 | 0.73 | CNR1 (0.32) | TBXAS1PSMB8PSMB9 | |
| SCHEMBL22549676 | 0.72 | MPO (0.39) | MPOCACNA1HPSMB8PSMB9PSMB5 | |
| SCHEMBL22354095 | 0.72 | DRD4 (0.44) | — | |
| SCHEMBL10202942 | 0.71 | MPO (0.41) | MPOCACNA1HPSMB8PSMB9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | MPO 4312/4885TBXAS1 740/4885CACNA1H 4649/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | MPO 4312/4885TBXAS1 740/4885CACNA1H 4649/4885 |
| US-20220162201-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | MPO 4821/4885TBXAS1 872/4885CACNA1H 4380/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | MPO 4312/4885TBXAS1 740/4885CACNA1H 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.